Amarin Corp Plc (AMRN)

[north40000]

That good, embargoed news from the Evaporate clinical trial was released (like Fidelity) in our TDA AMRN news section at 9:50 a.m. this morning, Saturday, as soon as that news was available to be released via a PR in accord with the usual scientific journal embargo restrictions.

In November 2018, we saw that the same procedure was used by Amarin and AHA in presenting the then late-breaking, embargoed news re results from the Reduce-It clinical trial. NEJM does not print “old” news either—our “news press kit” was on our chair when we were permitted to enter the convention hall in Chicago on Sunday, 11/18/2018, for Dr. Bhatt’s presentation. As Dr. Bhatt said later that afternoon, the on-line version of its print edition was immediately available.

I am sure today’s PR is intended for use as DTC reading material by the general public around the world(as health-related news), not just for us as Amarin investors to satisfy SEC requirements re disclosure of material information. I was happy, not sad, to see that PR this morning, inasmuch as it confirms my PCP’s opinions that Vascepa is stabilizing the small amount of plaque in my arterial walls. No new plaque appears. I was first prescribed Vascepa in April 2013.

I am not counting on a second, redundant PR appearing in my TDA news section Monday morning before market opens. After all, today’s PR will still be there in that news section, available to be read by anyone interested in reading it. Other agencies may pick it up for Sunday news media to report as they wish.

My point: there should be no complaint that the news appeared today for everyone to read, rather than Monday. The mantra of journalism is(parenthetically): “ We publish early all the news that’s fit to print”